Obviously, non-hematological disease manifestations (such as skeletal abnormalities in STAT3 DN) or irreversible remodeling processes (such as bronchiectasis/pneumatoceles in STAT3 DN or vascular changes in STAT1 GOF) cannot be successfully treated by HSCT. This evidence concerns the gene STAT3 and bronchiectasis.